The Road from Laboratory to Patient

Drug development is a multifaceted process aimed at enhancing patient health outcomes, involving collaborative efforts from researchers, regulatory bodies, and industry stakeholders. It begins with identifying disease-related biomolecules and validating potential drug candidates, followed by optimizing these leads for efficacy, safety, and pharmacokinetics. Subsequent preclinical tests evaluate safety and efficacy in animal and human models, leading to clinical trials that assess the drug’s safety, therapeutic efficacy, and patient impact across three phases. Despite rigorous testing and collaboration, the success rate in clinical drug development hovers around 10–15%. Major challenges contributing to the high failure rate include lack of efficacy, excessive toxicity, and suboptimal drug characteristics. Consequently, refining drug development approaches is essential to improve success probabilities, underscoring the intricate and demanding nature of bringing new therapeutic solutions from the lab to the market.